-+ 0.00%
-+ 0.00%
-+ 0.00%

Ensysce says Taiwan grants MPAR overdose-protection patent through 2042

PUBT·05/12/2026 12:01:09
Listen to the news
Ensysce says Taiwan grants MPAR overdose-protection patent through 2042
  • Ensysce Biosciences secured a Taiwan patent covering MPAR overdose-protection technology, extending jurisdictional protection through 2042.
  • Patent includes composition-of-matter claims, method-of-use claims tied to enzyme-cleavable prodrugs, controlled-release nafamostat.
  • Coverage expands U.S. Patent No. 12,599,578, issued April 14, 2026.
  • MPAR holds FDA Breakthrough Therapy designation, aims to curb opioid release in overdose scenarios while maintaining pain relief when used as directed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605120800ACCESSWRNAPR_____1165814) on May 12, 2026, and is solely responsible for the information contained therein.